• Denali Therapeutics reported second-quarter 2026 results with revenue of US$3.6 million and a net loss of US$127.55 million, narrowing its basic loss per share from continuing operations to US$0.68 compared with US$0.72 a year earlier.
• The company also completed the first full quarter of AVLAYAH’s commercial launch, advanced two Alzheimer’s programs into clinical development, and bolstered its balance sheet to more than US$1.10 billions in pro forma cash following the sale of a priority review voucher.
• Next, we’ll examine how AVLAYAH’s first full commercial quarter and Denali’s strengthened cash position influence the company’s investment narrative.

Find 50 companies with promising cash flow potential yet trading below their fair value.

What Is Denali Therapeutics' Investment Narrative?

To own Denali Therapeutics, you need to believe its blood brain barrier transport platform can translate scientific promise into durable products, starting with AVLAYAH and extending into larger neurodegenerative indications. The latest quarter underlines both sides of that bet: commercial AVLAYAH sales are not yet visible in the US$3.6 million revenue line, losses remain heavy at over US$120 million for the quarter, but the first full launch quarter and more than US$1.10 billions in pro forma cash modestly improve near term funding risk. Short term, the key catalysts still sit around AVLAYAH uptake, progress in the COMPASS confirmatory trial, and early execution in the two new Alzheimer’s programs. The recent news mainly strengthens the balance sheet rather than changing the fundamental binary clinical and commercial risks.

However, one risk around AVLAYAH’s confirmatory trial could materially alter the story. Denali Therapeutics' share price has been on the slide but might be dropping deeper into value territory. Find out whether it's a bargain at this price.

Exploring Other Perspectives

Two Simply Wall St Community fair value views span roughly US$3.74 to US$35.44, reflecting sharply different expectations just as AVLAYAH’s launch, pipeline progress and ongoing cash burn leave execution risk firmly in focus.

Explore 2 other fair value estimates on Denali Therapeutics - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Denali Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Denali Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Denali Therapeutics' overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.